In radiotherapy practice, one often needs to compare two dose distributions. Especially with the wide clinical implementation of intensity-modulated radiation therapy, software tools for quantitative dose (or fluence) distribution comparison are required for patient-specific quality assurance. Dose distribution comparison is not a trivial task since it has to be performed in both dose and spatial domains in order to be clinically relevant. Each of the existing comparison methods has its own strengths and weaknesses and there is room for improvement. In this work, we developed a general framework for comparing dose distributions. Using a new concept called maximum allowed dose difference (MADD), the comparison in both dose and spatial domains can be performed entirely in the dose domain. Formulae for calculating MADD values for various comparison methods, such as composite analysis and gamma index, have been derived. For convenience in clinical practice, a new measure called normalized dose difference (NDD) has also been proposed, which is the dose difference at a point scaled by the ratio of MADD to the predetermined dose acceptance tolerance. Unlike the simple dose difference test, NDD works in both low and high dose gradient regions because it considers both dose and spatial acceptance tolerances through MADD. The new method has been applied to a test case and a clinical example. It was found that the new method combines the merits of the existing methods (accurate, simple, clinically intuitive and insensitive to dose grid size) and can easily be implemented into any dose/intensity comparison tool.
Introduction
Dose distribution comparison is performed routinely in radiotherapy-related activities, e.g., patient-specific quality assurance (QA) using 2D/3D dosimeters for intensity-modulated radiation therapy (IMRT) (Low et al 1998b , 1999 , Childress et al 2002 Kapulsky et al 2002 , Low 2002 , Olch 2002 , Partridge et al 2002 , Zhu et al 2002 , Chang and Ling 2003 , Greer and Popescu 2003 , Jursinic and Nelms 2003 , Leal et al 2003 , Richardson et al 2003 , Tangboonduangjit et al 2003 , Warkentin et al 2003 , Bucciolini et al 2004 , Letourneau et al 2004 , Van Esch et al 2004 , Yeo et al 2004 . This is not a trivial task due to the fact that, to be clinically relevant, we need to compare dose distributions in both dose and spatial domains (Van Dyk et al 1993 , Childress et al 2002 . Several comparison methods have been developed based on various combinations of dose and spatial acceptance tolerances, including the simple dose difference test, the distance-toagreement (DTA) test (Van Dyk et al 1993 , Harms et al 1998 , the composite analysis for both dose difference and DTA (Shiu et al 1992 , Cheng et al 1996 , Harms et al 1998 , and the gamma-index method and its variations (Low et al 1998 , Depuydt et al 2002 , Bakai et al 2003 , Low and Dempsey 2003 .
Each comparison method has its own strength and weakness. The dose difference test, where the difference of two dose distributions is calculated point by point in dose domain, is the most straightforward and intuitive method. However, a large dose difference in a high dose gradient region is of less clinical significance since a small alignment error can translate to a big dose error (Van Dyk et al 1993 , Low et al 1998 . The DTA measure does not work in low dose gradient regions and therefore is often used in conjunction with the dose difference measure in a procedure called composite analysis (Shiu et al 1992 , Cheng et al 1996 , Harms et al 1998 . The composite analysis works in both high and low dose gradient regions. The comparison fails only when both dose difference and DTA criteria fail, and therefore the test is qualitative (pass/fail) rather than quantitative. The gamma-index calculation has recently become a popular dose comparison method due to its ability to produce a quantitative measure based on both dose and spatial criteria (Low et al 1998 , Depuydt et al 2002 , Bakai et al 2003 , Low and Dempsey 2003 , Van Esch et al 2004 . The weakness of gamma index is that its value, although quantitative, is less clinically intuitive than the dose difference. For example, we can easily understand a dose difference of 5 cGy or 5%, but a gamma index of 1.5 is harder to understand. In addition, gamma index does not have a sign, so we cannot tell which dose distribution has a higher value at the comparison point. Another weakness of this measure is that it is sensitive to dose grid resolution (Depuydt et al 2002, Low and Dempsey 2003) . Bakai et al (2003) tried to simplify the gamma-index calculation using an approximation based on the gradient of the reference dose distribution. The weakness of the gamma-index method was partially removed. However, we believe there is still room for improvement.
In this work, we developed a new concept (maximum allowed dose difference (MADD)) that can transform the dose comparison from both the dose and spatial domains into the dose domain alone. Using MADD, a new measure called normalized dose difference (NDD) was proposed that combines the merits of dose difference test, composite analysis and gamma index.
Theory

General idea
When we compare two dose distributions, we often look at their difference in both dose and spatial domains. At a specific comparison point, we compare the dose difference against a predetermined dose tolerance and the spatial difference against a predetermined spatial tolerance. The core idea of this work is to convert the comparison in the spatial domain into the comparison in the dose domain. To help understand this idea, we define a concept called equivalent dose tolerance that corresponds to the predetermined spatial tolerance. That is to say, if the spatial difference at a comparison point is smaller than the predetermined spatial tolerance, then the dose difference at that point must be smaller than the equivalent dose tolerance, and vice versa.
The predetermined dose tolerance and the equivalent dose tolerance are combined to form the maximum allowed dose difference (MADD), a spatially varying dose tolerance. If the absolute value of the dose difference at a given comparison point is smaller than or equal to MADD, the comparison passes in both dose and spatial domains. For composite analysis, the maximum of the equivalent dose tolerance and the predetermined dose tolerance is MADD. For the gamma-index method, the situation is more complicated. However, if we can compute MADD for every comparison point, we only need to compare the dose difference against MADD, and we do not need to compare the dose distributions in spatial domain at all.
The value of MADD varies from point to point. It is larger in high dose gradient region than in low dose gradient region, but it is always greater than the predetermined dose tolerance. For convenience of quantitative evaluation, we develop a method to scale the dose difference by the ratio of MADD and the predetermined dose tolerance, and then we can compare the normalized dose difference (NDD) to the predetermined dose tolerance which does not vary spatially.
In the following sections, we first present a theoretical framework for dose comparison by defining variables and concepts, and then present algorithms to calculate the equivalent dose tolerance and MADD for various dose comparison methods.
Theoretical framework for dose comparison
In this section, we outline a theoretical framework for dose comparison by summarizing some common notation and defining some new concepts and variables. Please note that this work is valid in 1D, 2D or 3D.
Reference dose distribution. A reference dose distribution, D r , is the dose distribution chosen as the ground truth to evaluate another dose distribution.
Test dose distribution.
A test dose distribution, D t , is the dose distribution to be evaluated against the reference dose distribution.
Between two dose distributions under comparison, the reference dose distribution is often the more accurate one. For example, when comparing calculation with measurement, the measured dose distribution is often the reference dose distribution and the calculated one is the test dose distribution. When comparing two calculated dose distributions, say, one by a Monte Carlo simulation and the other by a conventional algorithm, the former is often the reference dose distribution and the latter is the test dose distribution.
In clinical practice, the reference and test dose distributions can have different dimensions. For example, the test distribution can be 2D (film) and the reference can be a 3D dose calculation. The formalism developed in this work is very flexible and can easily handle those situations.
Comparison point. Dose comparison is performed point by point in (1D, 2D or 3D) space. At a comparison point, r, the reference dose distribution has a dose value D r (r) while the test dose distribution has a value D t (r). When we perform the comparison at this point in both dose and spatial domains, for the reference dose distribution we consider only this single point (r, D r (r)) and for the test dose distribution we check all the points in the neighbourhood of (r, D r (r)) to see if the agreement is within the predetermined tolerance or not. This scenario is illustrated in figure 1 , where we use an illustrative coordinate system with the horizontal axis being spatial location, r, the vertical axis being dose, D, and the origin being (r, D r (r)). figure 1 , the difference between the test dose value at an arbitrary point r and the reference dose value at the comparison point r is designated as D, i.e.,
Dose difference. As illustrated in
At the comparison point r, the dose difference between the test distribution and the reference distribution is written as
Distance-to-agreement. The spatial distance between an arbitrary point r and the comparison point r is written as r(r, r ) = |r − r|.
The distance-to-agreement (DTA) at the comparison point r is the distance from point r to the closest point r such that D(r, r ) = 0:
In figure 1, this point is r .
Predetermined dose tolerance. The predetermined dose tolerance, δD 0 , is the dose difference threshold determined before the comparison. If the absolute value of the dose difference at the comparison point r, |DD(r)|, is less than δD 0 , the comparison passes in the dose domain at this point.
Predetermined spatial tolerance. The predetermined spatial tolerance, δr 0 , is the spatial distance threshold determined before the comparison. If the DTA value at the comparison point r, DTA(r), is less than δr 0 , then the comparison passes in the spatial domain at this point.
Equivalent dose tolerance. Equivalent dose tolerance, denoted δD e (r), is a concept used to convert a comparison in the spatial domain into a comparison in the dose domain. In figure 2 , we can see that DD(r) > δD 0 , which means the comparison fails in dose domain at the comparison point r, and DTA(r) < δr 0 , which means the comparison passes in spatial domain. If we shift the test dose distribution D t away from the origin (r, D r (r)) along the dose axis, then the DTA value will keep increasing. We stop the shifting when DTA(r) = δr 0 . We call the shifted test dose distribution D t and define the equivalent dose tolerance as δD e (r) = D t (r) − D r (r). Now, checking DD(r) against δD e (r) is equivalent to checking DTA(r) against δr 0 . Therefore, if |DD(r)| < δD e (r), then we must have DTA(r) < δr 0 , and vice versa. This operation converts a comparison in the spatial domain into a comparison in the dose domain.
Dose difference test.
The dose difference test only compares two dose distributions in the dose domain, i.e., it only checks the dose difference at the comparison point, DD(r), against the predetermined dose tolerance, δD 0 . Clearly, this simple test is not sufficient in high dose gradient regions.
Composite analysis. Composite analysis is a commonly used dose comparison method that combines the dose difference test and the DTA test (Van Dyk et al 1993) . At the comparison point r, the comparison passes if |DD(r)| < δD 0 or DTA(r) < δr 0 .
γ -index method. This is another popular method that also combines dose and spatial criteria in dose comparison (Low et al 1998) . Using our nomenclature, the γ -index at the comparison point r is defined as
which represents the minimum distance in the combined spatial-dose domain, scaled by the predetermined dose tolerance and spatial tolerance, from the test dose distribution to the origin (r, D r (r)) (see figure 1) . The comparison passes when γ 1.
Box method. This is a new method for dose comparison that we propose in this paper. Imagine that, around the origin in figure 1, (r, D r (r) ), the spatial error bar (predetermined spatial tolerance δr 0 ) and the dose error bar (predetermined dose tolerance δD 0 ) form an 'error box', and the comparison passes as long as the test dose distribution intersects with the box, i.e., the passing condition is | D(r, r )| δD 0 and r(r, r ) δr 0 .
Binary pass/fail map. A (1D, 2D or 3D) binary pass/fail map is defined as a collection of comparison points with values being 0 for pass and 1 for failure. For composite analysis, this map is
where H (x) is the Heaviside step function with slightly modified definition here:
For the γ -index method, it is
and for the box method, it is
Acceptance region. Another way to understand various dose comparison methods is to look at their acceptance regions in the combined spatial-dose domain. The acceptance region refers to a region surrounding a point (r, D r (r)) in spatial-dose space, with the property that if any test point falls within the acceptance region, the test dose passes the comparison at the comparison point r. As shown in figure 3(a), the acceptance region for composite analysis, S c , consists of two line segments on the dose and spatial axes, and is given as
And as shown in figure 3(b), the acceptance region for the γ -index method is
For the box method, as illustrated in figure 3(c), its acceptance region is
where
L p norm representation of the acceptance region. It is interesting to point out that the abovementioned acceptance regions can be represented by the L p norm. The L p norm of a vector x = {x 1 , x 2 , . . . , x N } is defined as (Luenberger 1969 ) The most interesting L p norms include L 1 , L 2 and L ∞ norms.
If we plot the region in 2D where the L p norm is equal to 1, i.e., |x 1 | p + |x 2 | p = 1, then we should see that it is a square for p → ∞, a circle for p = 2 and a diamond for p = 1.
For p < 1, x p does not meet the technical criteria for being a norm and is called a measure. Especially for p → 0, the limit of x p does not even exist. However, for the sake of simplicity, in a slight abuse of terminology, we here still call x p a norm even for p < 1 and define the zero-norm as
For p < 1, the curve,
, becomes concave. For p = 0, the curve overlaps with the axes except at the origin. Now the dose comparison acceptance regions can be written in the framework of the L p norm:
with S 0 being the composite analysis, S 2 the γ -index method and S ∞ the box method. With this notation, we can easily define various different forms of acceptance region as long as they make sense in practice.
Maximum allowed dose difference. The maximum allowed dose difference (MADD) is a more general concept than the equivalent dose tolerance. The equivalent dose tolerance corresponds to the predetermined spatial tolerance, while MADD corresponds to the acceptance region. MADD defines the pass/fail boundary at the comparison point r such that if |DD(r)| = MADD(r), then the test dose distribution (here we mean the corresponding hyperplane in spatial-dose domain) must be tangential to the acceptance region. If |DD(r)| < MADD(r), the test dose distribution must intersect with the acceptance region and the comparison passes. If |DD(r)| > MADD(r), the test dose distribution must not intersect with the acceptance region and the comparison fails. This new concept and its difference from the equivalent dose tolerance are illustrated in figure 4 .
Using the concept of MADD, the acceptance region in the spatial-dose domain is condensed into a single value in the dose domain. Therefore, the dose comparison can be performed solely in the dose domain, no matter which method we use (composite analysis, gamma index, box method). That is to say, we can calculate the dose difference at every point and compare that with the MADD value at each point. The comparison passes when the dose difference is smaller than or equal to the MADD value. Therefore, when using MADD, the binary pass/fail map is
For composite analysis, MADD at the comparison point r is given as MADD(r) = max(δD 0 , δD e (r)).
For the γ -index method and the box method, MADD(r) max(δD 0 , δD e (r)). The calculation of MADD is more complex and will be presented later.
Normalized dose difference. In practice, it is not very convenient to quantitatively evaluate the comparison results when using MADD. Therefore, instead of changing dose difference acceptance criterion from δD 0 to MADD(r), we can normalize the dose difference distribution so that at every point the dose difference acceptance criterion is still δD 0 . We define the normalized dose difference (NDD) as
where n(r) is a normalization factor at the comparison point r: In low dose gradient regions, n = 1 and NDD(r) = DD(r), meaning that there is no normalization. In high dose gradient regions, n > 1 and NDD(r) < DD(r), which means that the dose difference is scaled down. Care must still be taken when interpreting NDD, since it is in units of scaled dose not absolute dose. When using NDD, the pass/fail binary map is
Calculation of the equivalent dose tolerance
The equivalent dose tolerance δD e (r) can be calculated numerically in a brute force way, by shifting the test dose distribution along the dose axis until DTA(r) = δr 0 . However, this method is very inefficient. Here, we develop an algorithm for fast calculation of δD e (r). As shown in figure 5 , we have DTA(r) δr 0 if and only if the test dose distribution intersects with the line segment (|r − r| δr 0 ) on the space axis, and the intersection occurs if and only if the maximum of D t over the region (|r − r| δr 0 ) is bigger than D r (r), and the minimum is smaller. We define
Here, δD + (r) and δD − (r) refer to differences between the test dose at r and the maximum and minimum test doses over the region within the spatial tolerance. The test dose distribution intersects with the line segment (|r − r| δr 0 ) if and only if we have The above equations can be rewritten as
with DD(r) being defined by equation (2). Equation (28) can be simplified as
The upper limit of |DD( r)| is then the equivalent dose tolerance corresponding to the spatial tolerance, i.e., δD e (r) = max
Calculation of the maximum allowed dose difference
At the comparison point r, the test dose distribution D t agrees with the reference dose distribution MADD is a function of test dose distribution shape near point r and the acceptance region shape. The calculation of MADD is similar to but more complex than that of δD e (r). The difference is, instead of the line segment on the spatial axis, we have an acceptance region S k . However, we can decompose the acceptance region into a stack of 'slices' at various dose levels:
where g k (ξ ) is the acceptance 'slice' at dose level D r (r) + ξ and ξ is a free variable in dose domain. The calculation of the 'δD e (r)' value for each slice is similar to the method we developed in the previous section. The MADD value corresponding to the acceptance region is then the maximum of the 'δD e (r)' values for all slices. Let us first consider one slice of the acceptance region at the dose level D r (r)+ξ , as shown in figure 6 . From the previous section, we know the 'δD e (r)' value for this line segment is
Corresponding to the whole acceptance region S k , we can compute the maximum allowed dose difference by combining all segments:
Considering equations (10)- (12) and (31), we obtain the MADD for each acceptance region, respectively. For composite analysis, it is MADD c (r) = max δD 0 , max
which is consistent with equations (21) and (30). For the γ -index method, we have
For the box method, we have
We can use the gradient of the test dose distribution, |∇D t (r)|, to linearly approximate D t and further simplify equations (34)- (36):
where β = |∇D t (r)| · δr 0 /δD 0 is a dimensionless variable proportional to the dose gradient. It is clear that what really matters is the shape (characterized by gradient in linear approximation) of the test, not reference, dose distribution, if one follows the original definitions of composite analysis and gamma-index test (Bakai et al 2003) . We should use equations (37)- (39) with caution because the increase of computational efficiency by using linear approximation may not be able to compensate for the loss of accuracy, especially for noisy test dose distribution. Therefore, we do not recommend the use of equations (37)- (39) for MADD calculation.
Notes for numerical calculations
For composite analysis, we do not have to calculate DTA. Equation (6) can be equivalently written as
Here, the first term checks if the dose difference is smaller than dose criterion δD 0 and the second term checks if the test dose distribution crosses the dose level D r (r) within the region of δr 0 . The search in the second term stops as soon as it hits the first zero. Gamma-index calculation using equation (5) is not straightforward. There are two issues that we need to pay attention to, namely the search region and the dose grid resolution. Apparently, if the search region is too small, we may overestimate the gamma value, and on the other hand, if the search region is too large, we waste time. So an estimate of the minimum search region at each comparison point is necessary. Gamma calculation is also very sensitive to the resolution of dose distributions (Depuydt et al 2002, Low and Dempsey 2003) . Here, we propose an iterative multi-resolution algorithm to calculate gamma value γ (r) at the comparison point r as follows: The gamma index can also be rewritten into a NDD-like quantity as
If one prefers to calculate gamma index, the result can also be presented as NDD γ (r) because, compared to the gamma index, it has a sign and is in the unit of dose. The pass/fail maps of NDD γ will be the same as those of NDD γ , calculated using equations (22)- (24). For the box method, equation (9) can be rewritten for the sake of computational convenience as
The search finishes as soon as it finds the first zero value of H (| D(r, r )| − δD 0 ). Numerical calculation of MADD values using equations (34)- (36) is straightforward and not sensitive to the dose grid resolution. The interpolation only needs to be performed at the boundary of the spatial search region (δr 0 for equations (34) and (36) and δr 0 1 − (ξ/δD 0 ) 2 for equation (35)) when it falls in between grid points.
Application examples
The developed new dose comparison methods have been tested using a simple 2D case. The reference dose distribution, as shown in figure 7(a), is a 10 × 10 cm 2 6 MV photon beam
(c) (f) Figure 7 . (a) Reference dose distribution, (b) test dose distribution, (c) dose difference distribution, and gamma distributions calculated using fixed dose grid resolutions of (d) 1 mm and (e) 0.5 mm, and (f) using iterative multiple-resolution algorithm given in section 2.5 with initial pixel size of 1 mm.
profile reconstructed using an empirical formula from Low and Dempsey (2003) . The dose distribution is normalized to the maximum dose which happens to be at the beam central axis in the simulated beam. The test dose distribution, as shown in figure 7(b), is converted from the reference dose distribution by (1) adding 0.05 to the pixels that have dose values greater than 0.95 and (2) then rotating the dose distribution around the beam central axis counterclockwise 6.8
• . The amount of the rotation was chosen so that about 50% of time the field edges of the test and reference beams are within the DTA tolerance. The dose difference distribution, which is the result of the test dose distribution minus the reference dose distribution point by point, is shown in figure 7(c). As expected, within the beam central area the difference is about 0.05 due to the dose increasing, and we see large positive/negative difference at the beam edge due to the rotation.
The pixel size is 1 mm in this study unless otherwise specified. We use 0.03 for δD 0 and 3 mm for δr 0 for all the following analyses. Figures 7(d) and (e) show the gamma-index distributions calculated by using equation (5) directly at fixed pixel sizes of 1 mm and 0.5 mm, respectively. It can be seen that the resolution-dependent artefacts are reduced with the increase of dose grid resolution, but still obvious even for very small pixel size of 0.5 mm. This is because equation (5) is very sensitive to dose grid resolution. To solve this problem, a very fine dose grid should be used in high dose gradient regions (Low and Dempsey 2003) . The result from the iterative multiple-resolution algorithm described in section 2.5 is given in figure 7(f). We can see that the artefacts are gone. We can also see that, inside the beam, the gamma method indicates a disagreement between the two distributions because the 0.05 dose increase is greater than 0.03 dose criterion and the dose gradient is low. For dose errors caused by the misalignment at the beam edge, some points still pass gamma test due to the 3 mm spatial criterion.
The NDD and corresponding pass/fail maps calculated using equations (34)- (36) and (22)- (24) for various acceptance regions are given in figure 8. The search in space only needs to be performed at dose grid points. When computing equation (35), the search step in dose domain, i.e., the 'slice thickness', is determined as ξ = x/δr 0 · δD 0 , where the spatial resolution x is 1 mm. From the composite analysis, to the gamma index and to the box method, the acceptance region becomes larger and larger, which means the number of points that fail the comparison becomes fewer and fewer. This trend can easily be seen in figure 8 . The pass/fail maps have also been compared with those calculated using traditional methods (equations (6), (8) and (9)) pixel by pixel and no difference was found.
The developed methods for dose comparison have been coded in MatLab and can be used for clinically realistic cases. The code is in public domain and available to readers on request. Here for illustration purpose we present an application example of this code. Two 3D dose distributions are compared. A five-field lung IMRT plan was calculated using a Monte Carlo dose engine called MCSIM (Ma et al 2002) as well as a pencil beam algorithm in a commercial planning system called CORVUS (North American Scientific, Chatsworth, CA). The Monte Carlo dose distribution is treated here as the reference dose distribution while the result from CORVUS is used as the test dose distribution. Both dose distributions have 128 × 92 × 85 voxels with the voxel size of 3.5 mm × 3.0 mm × 3.0 mm and normalized to the prescribed dose. We use 3% for δD 0 and 3 mm for δr 0 . Figure 9(a) shows the two dose distributions overlaid on a CT slice. The thick line is Monte Carlo dose distribution and the thin line represents CORVUS dose distribution. Figures 9(b) and (c) give the dose difference distribution and the normalized dose difference distribution. The NDD distribution was calculated for the acceptance region of gamma index using equation (35) . The MADD distribution is shown in figure 9(d) and the pass/fail maps corresponding to the dose difference and the NDD are shown in figures 9(e) and 9(f), respectively. 
Summary
A general framework has been proposed for comparison of spatially varying dose distributions. In this framework, various dose comparison methods (composite analysis, gamma index and box method) differ only in their acceptance regions. A new concept called maximum allowed dose difference (MADD) has been developed, which can transform the acceptance region into a dose tolerance value (i.e., MADD) at each dose point. Thus, the dose comparison can be accurately performed solely in dose domain. Formulae for calculating MADD for acceptance regions of composite analysis, gamma index and box method have been derived. Numerical implementation of these formulae is straightforward and is not sensitive to the dose grid resolution. For convenience in clinical practice, a new variable called normalized dose difference (NDD) has been proposed, which is the dose difference distribution scaled by the ratio of MADD to the dose criterion. Compared to the simple dose difference test, NDD scales down the dose difference in high dose gradient regions and represents the difference of two dose distributions in a more clinically meaningful way in both low and high dose gradient regions. To see if two distributions agree or not at one point, we only need to compare the NDD value with the original dose acceptance criterion. The proposed new method combines the merits of the existing methods (accurate, simple, clinically intuitive and insensitive to dose grid size) and can easily be implemented in any dose/intensity comparison tool.
